By Lisa Kerner
Charlotte, N.C., Aug. 28 - Zogenix, Inc. said it raised $60 million in a series A private financing.
Proceeds from the financing were used to fund the acquisition and development of the Intraject technology assets from Aradigm Corp.
Intraject sumatriptan is the first needle-free, single-use, disposable, subcutaneous delivery system to compete in the $2.5 billion triptan segment of the migraine market, according to a news release.
Clarus Ventures and Domain Associates, LLC co-led the financing round, joined by BA Venture Partners, Thomas, McNerney & Partners and Life Science Angels, Inc.
Zogenix named founder Cam L. Garner, former chairman and chief executive officer of Dura Pharmaceuticals, as its board of directors chairman.
Other members of the board include Kurt C. Wheeler, managing director of Clarus Ventures; James C. Blair, partner of Domain Associates; Louis C. Bock, managing director of BA Venture Partners; and Alex Zisson, partner of Thomas, McNerney & Partners.
San Diego-base Zogenix is a privately held pharmaceutical company focused on medicines to treat central nervous system disorders and pain.
| Issuer: | Zogenix, Inc.
|
| Issue: | Series A financing
|
| Amount: | $60 million
|
| Investors: | Clarus Ventures and Domain Associates, LLC (co-led), BA Venture Partners, Thomas, McNerney & Partners and Life Science Angels, Inc.
|
| Announcement date: | Aug. 28
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
